Thymosin Alpha-1: The Immune Peptide Evidence Reviewed (2026)

Last updated: June 2026

Medical disclaimer: This article is for informational purposes only and is not medical advice. Thymosin alpha-1 is approved in some countries but is NOT FDA-approved in the United States. Do not start, stop, or change any treatment based on what you read here. Consult a licensed clinician.

Thymosin alpha-1 is one of the most studied immune peptides on the planet. It has decades of human trials behind it. It is sold as a real drug in dozens of countries. And it is not approved in the United States.

That gap is the whole story. The science is genuine, but the quality is mixed. This review walks through what the evidence actually shows, where the peptide is legal, and what stays unknown.

What is thymosin alpha-1 and how does it work?

Thymosin alpha-1 is a synthetic 28-amino-acid peptide that copies a natural fragment of the thymus protein prothymosin alpha, and it works by nudging T-cell maturation and immune balance rather than killing pathogens directly. It is also called thymalfasin. The drug version is branded Zadaxin.

Allan Goldstein's lab at George Washington University isolated and characterized the peptide in 1977. Enrico Garaci and colleagues spent the following decades mapping its biology. Their combined work is the backbone of the field (Costantini et al., comprehensive review, 2020, PMC7747025).

The peptide is an immune modulator, not an immune booster. It signals through Toll-like receptor 9 (TLR9) on dendritic cells. That triggers a chain (MyD88 to IRF7) that helps mature naive T-cells into working CD4 and CD8 cells.

In practice, that means it can push a weak immune system to respond better. It may also calm an overactive one. This two-way action is why researchers test it in infections, sepsis, and cancer alike.

If you are new to peptides as a category, our 15 questions to ask before starting peptide therapy covers the basics of how to read claims like these with a skeptical eye.

What does the infectious-disease evidence show?

The strongest infectious-disease signal is in sepsis, where several meta-analyses report lower mortality, but the benefit shrinks or vanishes when you look only at large, high-quality trials. Hepatitis B has real randomized data too, though guidelines still do not recommend it.

Start with sepsis. A 2016 systematic review of randomized trials found lower death rates with thymosin alpha-1 (Li et al., 2016, PMID 27633969). An earlier pooled analysis of 12 trials and 1,480 patients found the same trend (Liu et al., 2014, PMID 25532482).

A newer 2025 meta-analysis of 11 trials again showed reduced 28-day mortality (odds ratio 0.73). But the authors flagged a key catch. The benefit did not hold in the high-quality, multi-center subgroups (2025 meta-analysis, PMID 40969554).

That pattern matters. When small studies show an effect and big rigorous ones do not, the small studies are often the problem. Most sepsis trials were single-country and modest in size.

Hepatitis B has older but cleaner randomized trials. A 1998 controlled trial found a complete virological response in about 41% of treated patients versus 9% of controls (Chien et al., 1998, PMID 9581695). A phase III placebo-controlled study followed (Andreone et al., 1999, PMID 10607256).

A 2022 Cochrane review pooled the hepatitis B data and stayed cautious. It found a roughly three-fold virological response advantage at 12 months post-treatment, but no clear effect on hard outcomes, and rated the certainty low (Htet et al., Cochrane, 2022). Most hepatitis treatment guidelines do not list the peptide.

Then there is COVID-19. Early 2020 China cohorts generated a lot of buzz. The most cited, in Clinical Infectious Diseases, reported lower mortality in severe patients alongside restored lymphocyte counts (Liu et al., 2020, PMID 32442287).

Be honest about that data. These were retrospective cohorts, not randomized trials. A separate multicenter study saw a mortality drop in critical patients (Wu et al., 2020, PMID 33208294), while a later cohort found no clear benefit (2021 multicenter cohort, PMID 34408744). The COVID evidence is suggestive, not settled.

What does the cancer adjuvant evidence show?

The cancer data is mostly older, mostly as an add-on to chemotherapy, and mixed; the largest randomized trial in melanoma did not clearly beat standard care. The peptide is studied as an immune adjunct, not a standalone cancer drug.

The headline trial is large. A randomized study assigned 488 metastatic melanoma patients across treatment arms combining thymosin alpha-1, interferon, and dacarbazine (Maio et al., J Clin Oncol, 2010, PMID 20194853). The results did not establish a clear survival win for the peptide.

Lung cancer work is smaller and older. Garaci's group ran chemoimmunotherapy protocols pairing the peptide with cisplatin-based regimens, reporting responses in early-phase studies. These were not large confirmatory trials.

One more recent observational signal comes from liver cancer. A propensity-matched analysis suggested better survival after surgery for hepatitis-B-related liver cancer in patients who got the peptide (HCC post-resection analysis, PMC8137107). Observational means it cannot prove cause.

The honest read: thymosin alpha-1 has a plausible immune-oncology rationale, and a few positive signals, but no modern phase III trial that would change cancer practice.

<a id="study-table"></a>

How does the evidence stack up? (study table)

Study / Trial (author, year)	Condition	Sample (n)	Primary finding
Chien et al., 1998 (PMID 9581695)	Chronic hepatitis B	98	Complete virological response ~41% vs ~9% control
Andreone et al., 1999 (PMID 10607256)	Chronic hepatitis B	~99	Phase III placebo-controlled; modest response benefit
Htet et al., Cochrane, 2022	Chronic hepatitis B	353 (5 RCTs)	~3x virological response at 12 mo; low certainty
Liu et al., 2014 (PMID 25532482)	Sepsis	1,480 (12 trials)	Trend to lower all-cause mortality (RR 0.68)
Li et al., 2016 (PMID 27633969)	Sepsis	530 (10 RCTs)	Lower mortality (RR 0.59); small trials
2025 meta-analysis (PMID 40969554)	Sepsis	1,927 (11 RCTs)	Lower 28-day mortality (OR 0.73); not in high-quality subgroup
Liu et al., 2020 (PMID 32442287)	Severe COVID-19	76	Lower mortality; retrospective cohort, not RCT
Wu et al., 2020 (PMID 33208294)	Critical COVID-19	334	Lower 28-day mortality; retrospective
Maio et al., 2010 (PMID 20194853)	Metastatic melanoma	488	No clear survival benefit added to chemo
HCC post-resection (PMC8137107)	Liver cancer (post-surgery)	propensity-matched	Better survival signal; observational

Where is thymosin alpha-1 approved vs not?

Thymosin alpha-1 is approved as the prescription drug Zadaxin (thymalfasin) in more than 30 countries, mainly for chronic hepatitis B, but it has never been FDA-approved in the United States. The US status is the single most important fact for an American reader.

Outside the US, the picture is broad. SciClone Pharmaceuticals brought Zadaxin to market across Asia, Europe, the Middle East, and Latin America. Approved uses vary by country and include chronic hepatitis B, chronic hepatitis C, and as an immune adjunct to vaccines in some regions.

In the United States, it is a different world. The peptide holds FDA orphan-drug designations for malignant melanoma and liver cancer, but designation is not approval. No FDA-approved thymosin alpha-1 product exists.

The compounding angle moved a lot recently. In September 2023, the FDA put thymosin alpha-1 on Category 2 of its interim 503A bulk-substances list, citing immunogenicity and impurity concerns. That effectively warned compounders off it.

Then it shifted again. On September 27, 2024, the FDA removed thymosin alpha-1 from Category 2, after the nomination backing it was withdrawn (FDA bulk drug substance review, 2024). Removal is not a green light. It just kicked the substance toward a future Pharmacy Compounding Advisory Committee (PCAC) decision, with reviews scheduled into 2026.

So in 2026 the US reality is murky. The peptide is widely sold by "research-use only" vendors with not-for-human-use labeling, which is a legal and quality gray zone. We cover this in our peptide legality guide and the difference between compounded peptides and research chemicals.

What are the reported dosing forms?

In the literature and on approved labels, thymosin alpha-1 is given as a subcutaneous injection, typically dosed by body weight, but US gray-market products carry no verified dosing and no quality guarantee. This section is descriptive, not a protocol.

Approved Zadaxin labeling for hepatitis uses a subcutaneous injection given twice weekly over several months. Dosing in trials was often pegged to body surface area or fixed milligram amounts. The exact regimen always tracked the specific condition studied.

Sepsis and COVID trials used different, often higher, in-hospital dosing under medical supervision. Those numbers do not transfer to at-home use.

For US buyers, there is a hard wall. Research-grade vials are not tested for human dosing, sterility, or peptide purity in the way an approved drug is. Vendor quality varies enormously, which is why third-party testing matters; see our best peptide vendors guide.

What are the risks and unknowns?

Thymosin alpha-1 looks well-tolerated in trials, with mostly mild injection-site reactions, but the big unknowns are long-term safety, immunogenicity, and whether the small-trial benefits are real. A clean short-term safety record is not the same as proven long-term safety.

In published trials, side effects were generally minor. Injection-site redness and discomfort were the most common. Serious adverse events were uncommon in the studied populations.

The FDA's stated worry is different. As a 28-amino-acid peptide given by injection, it could trigger immune reactions (immunogenicity), and impurities or aggregation in poorly made product could worsen that risk. That concern drove the 2023 Category 2 listing.

The deeper unknown is efficacy. The recurring story across sepsis and hepatitis is that small studies look good and rigorous ones look flat. That is a classic signature of publication bias and weak trial design.

There is no long-term US safety surveillance because there is no approved US product. Anyone using gray-market material is, in effect, their own uncontrolled experiment. Run through our 15 questions before starting peptide therapy before going near it.

The bottom line

Thymosin alpha-1 is a real drug somewhere. Just not here. It is approved as Zadaxin in 30-plus countries and has more human data than almost any other research peptide.

But the evidence is uneven. Sepsis and hepatitis B show signals that fade under scrutiny. COVID data is retrospective. Cancer data is old and mixed.

In the US in 2026, it is not FDA-approved, sits in compounding limbo, and is mostly sold as a research chemical with no quality guarantee. The science deserves respect. The supply chain does not. Talk to a licensed clinician before treating any of this as actionable.

Related Reading

• Peptide legality guide (2026)
• Compounded peptides vs research chemicals (2026)
• Best peptide vendors, third-party tested (2026)

Frequently asked questions

Is thymosin alpha-1 FDA-approved? No. As of 2026, there is no FDA-approved thymosin alpha-1 product in the United States. It holds orphan-drug designations for melanoma and liver cancer, but designation is not approval, and it is sold abroad as the drug Zadaxin.

What is thymosin alpha-1 used for in countries where it is approved? In the 30-plus countries where Zadaxin (thymalfasin) is approved, the main use is chronic hepatitis B. Some countries also approve it for chronic hepatitis C and as an immune adjunct to vaccines in weakened patients.

Does thymosin alpha-1 actually work for sepsis? Several meta-analyses report lower mortality, but the benefit weakens or disappears when only large, high-quality trials are analyzed. A 2025 review (PMID 40969554) found no mortality benefit in its high-quality subgroup, so the answer is unproven.

Is thymosin alpha-1 the same as thymalfasin or Zadaxin? Yes. Thymalfasin is the generic drug name for thymosin alpha-1, and Zadaxin is the brand name marketed by SciClone. All three terms refer to the same 28-amino-acid peptide.

Is it legal to buy thymosin alpha-1 in the US? There is no FDA-approved version to buy as a drug. The FDA removed it from the Category 2 compounding list in September 2024, pending advisory-committee review. Most US sales are "research-use only" products with not-for-human-use labeling, a legal gray zone.

Researched and drafted by Theo Park, an AI editorial persona at Peptide Front, against published sources. Reviewed by our editorial team.